Clinical Trials Directory

Trials / Completed

CompletedNCT01267396

Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg Under Fasting Conditions

Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr. Reddy's Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg Tablet (Pfizer, USA)Under Fasting Conditions in Healthy Human Adult Subjects.

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
32 (actual)
Sponsor
Dr. Reddy's Laboratories Limited · Industry
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The objective of this study was to compare and evaluate the single-dose oral bioavailability of the test formulation of Sertraline Hydrochloride 100 mg tablets (Dr. Reddy's Laboratories Limited) with the reference formulation ZOLOFT® 100 mg Tablet (Pfizer)under fasting conditions in healthy adult human subjects.

Detailed description

Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover, Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr. Reddy's Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg Tablet (Pfizer, USA)Under Fasting Conditions in Healthy Human Adult Subjects. 32 healthy, adult, human male subjects were enrolled in the study and all the subjected completed all the periods.

Conditions

Interventions

TypeNameDescription
DRUGSertralineSertraline Hydrochloride Tablets 100 mg

Timeline

Start date
2006-09-01
Primary completion
2006-09-01
Completion
2006-10-01
First posted
2010-12-28
Last updated
2012-01-11

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT01267396. Inclusion in this directory is not an endorsement.

Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg Under Fasting Conditions (NCT01267396) · Clinical Trials Directory